Literature DB >> 2889459

Peripheral vascular effects of beta-adrenoceptor blockade: comparison of two agents.

E D Cooke1, M B Maltz, R E Smith, S A Bowcock, C J Watkins, A J Camm.   

Abstract

1. The effects of atenolol (100 mg), a beta 1-adrenoceptor blocker, and bevantolol (200 mg) were compared on heart rate, blood pressure, lung function and on the peripheral circulation in normal volunteers before and after isoprenaline infusion. Recordings were obtained 2 and 24 h following a single dose and 24 h after continuous dosage for 7 days. 2. The effect of atenolol on the blockade of beta-adrenergic stimuli, as measured by the ability to reduce isoprenaline-induced tachycardia, was greater than that of bevantolol. Though both drugs achieved a similar reduction in systolic pressure there was a significantly greater reduction in diastolic pressure with bevantolol. The lung function tests gave similar results to those with other beta-adrenoceptor blockers. 3. Atenolol produced a fall in peripheral blood flow consistent with unopposed peripheral alpha-adrenoceptor stimulation. The effect of bevantolol differs from that of atenolol, an initial fall in peripheral blood flow being followed by a rapid recovery to baseline or greater. This effect may be due to partial alpha-adrenoceptor agonist activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2889459      PMCID: PMC1386258          DOI: 10.1111/j.1365-2125.1987.tb03181.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  A vascular abnormality in hypertension. A study of blood flow in the forearm.

Authors:  J CONWAY
Journal:  Circulation       Date:  1963-04       Impact factor: 29.690

2.  Peripheral skin necrosis complicating beta-blockage.

Authors:  R Gokal; T L Dornan; J G Ledingham
Journal:  Br Med J       Date:  1979-03-17

3.  Cardioselectivity studies.

Authors:  M K Benson
Journal:  Proc R Soc Med       Date:  1977

4.  Beta-adrenergic blockade by 3-[3-(substituted amino)-2-hydroxypropox]-5-hydroxybenzyl alcohols.

Authors:  C F Schwender; R E Pike; J Shavel
Journal:  J Med Chem       Date:  1975-02       Impact factor: 7.446

5.  Propranolol in hypertension: a study of long-term therapy, 1964-1970.

Authors:  F J Zacharias; K J Cowen; J Prestt; J Vickers; B G Wall
Journal:  Am Heart J       Date:  1972-06       Impact factor: 4.749

6.  Cold sensitivity in essential hypertension: the effect of beta- and combined alpha- and beta-blockade.

Authors:  E D Cooke; S A Bowcock; A T Smith
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile.

Authors:  I D Dukes; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

8.  Once- and twice-daily bevantolol for systemic hypertension using 24-hour ambulatory intraarterial blood pressure recording.

Authors:  I M Al-Khawaja; M P Caruana; H Prince; J Whittington; E B Raftery
Journal:  Am J Cardiol       Date:  1986-11-26       Impact factor: 2.778

9.  Effects of bevantolol and atenolol on symptoms, exercise tolerance and metabolic risk factors in angina pectoris.

Authors:  J T Salonen; E Taskinen; R Salonen; K Seppänen; J Venäläinen; R Rauramaa
Journal:  Am J Cardiol       Date:  1986-11-26       Impact factor: 2.778

10.  Comparison of bevantolol and atenolol for systemic hypertension.

Authors:  G J Fairhurst
Journal:  Am J Cardiol       Date:  1986-11-26       Impact factor: 2.778

View more
  2 in total

1.  A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension.

Authors:  R Lewis; D Maclean; C Ioannides; A Johnston; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

Review 2.  Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  W H Frishman; R J Goldberg; P Benfield
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.